Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.

Item
http://www.wikidata.org/entity/Q33429869
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyondPrimary and acquired resistance to biologic therapies in gastrointestinal cancers.Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.Current therapeutic landscape for advanced gastroesophageal cancers.Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.Next generation sequencing-based emerging trends in molecular biology of gastric cancer.Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells.New therapeutic options opened by the molecular classification of gastric cancer.
P2860

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.

Item
http://www.wikidata.org/entity/Q33429869
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Optimal regimen of trastuzumab ...... a multicenter, phase II trial.
@ast
Optimal regimen of trastuzumab ...... a multicenter, phase II trial.
@en
type
label
Optimal regimen of trastuzumab ...... a multicenter, phase II trial.
@ast
Optimal regimen of trastuzumab ...... a multicenter, phase II trial.
@en
prefLabel
Optimal regimen of trastuzumab ...... a multicenter, phase II trial.
@ast
Optimal regimen of trastuzumab ...... a multicenter, phase II trial.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P478
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Optimal regimen of trastuzumab ...... a multicenter, phase II trial.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P478
P577
P5875
P6179
P698
P921
P932